SBIR Phase I:Magnetic Vectoring of Nanoparticle Drug-Carriers for Tumor-Specific Delivery of Chemotherapeutics

Period of Performance: 01/01/2010 - 12/31/2010

$150K

Phase 1 SBIR

Recipient Firm

NBMI
124 N Bryant Ave, Suite C-3
Edmond, OK 73034
Principal Investigator

Abstract

This Small Business Innovation Research (SBIR) Phase I project aims to develop a tumor-specific delivery technology based on the use of superparamagnetic nanoparticles as vehicles for the delivery of paclitaxel. The magnetic vectoring drug delivery platform uses external shaped magnetic field gradients to concentrate nanoparticle-drug constructs at a target site, followed by tumor extravasation. This project will focus on the treatment of superficial tumors, such as locally advanced breast cancers (LABC). These tumors pose a difficult and, as yet, unresolved clinical problem as most patients presenting with this disease will experience resistance and pronounced toxicity for current therapeutics. Therefore, a significant need exists for advanced therapies that can improve patient outcomes. A key distinguishing feature of this technology is the potential to overcome tumor interstitial pressure that normally tends to thwart free drug penetration.